Waterfall plot for best response by RECIST version 1.1.
ADVERSE EVENTS
Genomic results labelled with “G” represent germline alterations.Progression-free survival (Progression-free survival (The median number of cycles of ramucirumab and olaparib was 5 (range 1–43), and 14 (27%) of patients required a dose reduction of olaparib. The most frequently reported treatment-related adverse events (TRAE) at any grade that occurred in more than 10% of patients are outlined in Table Frequency of treatment-related adverse events and laboratory abnormalities with >10% incidence.